talking biotech

Podcast: GMO AquAdvantage salmon headed for US grocery stores after 15 years of regulatory review

, | March 27, 2019
HOST OVERVIEW
Kevin Folta: University of Florida plant geneticist Kevin Folta launched Talking Biotech in 2015.    More details
unnamed file
AquaBounty CEO Sylvia Wulf.

When the transgenic AquAdvantage salmon was first developed in 1989, the goal was simple: engineer a fast-growing fish that required fewer resources and provided an equivalent amount of salmon compared to its non-GMO counterpart. 30 years later, AquAdvantage salmon is expected to boost the sustainability of fish farming and provide consumers with an affordable, high-quality source of protein as it enters the market. Biotech firm AquaBounty anticipates its GMO salmon will be in US grocery stores in late 2020.

As the first (and so far only) GMO animal to be approved for human consumption, AquAdvantage salmon endured 15 years of regulatory review as officials in the US and Canada thoroughly evaluated its potential nutritional and environmental impacts. On this episode of the Talking Biotech podcast, plant geneticist Kevin Folta speaks with Sylvia Wulf, CEO and President of AquaBounty Technologies. They discuss the genesis of GMO salmon, how the fish will be kept out of the oceans, and why politics stalled the introduction of AquAdvantage for so long.

 

Follow AquaBounty on Twitter @AquaBountyTech and visit the company’s website.

Kevin M. Folta is a professor in the Horticultural Sciences Department at the University of Florida. Follow professor Folta on Twitter @kevinfolta and email your questions to [email protected]

The Talking Biotech podcast, produced by Kevin Folta, is available for listening or subscription:

Apple Podcasts | Android | Email | Google Podcasts | Stitcher | RSS | Player FM | Pod Directory | TuneIn

GLP Podcast Hosts

Listen to more episodes

glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.